Update
$OCUL.US$ Ocular Therapeutix Has Received FDA Written Response That Phase 3 Sol-r Trial Is Appropriate For Use As The Company's Second Adequate And Well Controlled Study Of Axpaxli (Axitinib Intravitreal Implant, Also Known As OTX-TKI) For Wet Age-related Macular Degeneration
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
